https://www.pharmaradar360.com/article/9a8cc9f87b8f7864PharmaRadar360en2026-04-09T02:00:00.000ZPharmac to fund two new combination treatments, and widen access to another, for people with a type of blood cancerhttps://www.pharmaradar360.com/article/194ed91c950cdccbPharmaRadar360en2026-04-08T22:00:00.000ZInvestor Access Event (Paris, France)https://www.pharmaradar360.com/article/4beffe81f1abf7ecPharmaRadar360en2026-04-08T19:57:52.000ZACRP Fellow Touts the Benefits of Bringing Clinical Research Stakeholders Togetherhttps://www.pharmaradar360.com/article/6b53c148356fbaf3PharmaRadar360en2026-04-08T18:30:54.167ZSigns You May Need a New Pillowhttps://www.pharmaradar360.com/article/e80c22b3a4bc5d28PharmaRadar360en2026-04-08T16:05:00.000ZAbbVie moves to close loopholes and strengthen accountability in 340B programhttps://www.pharmaradar360.com/article/55af2a71d1758243PharmaRadar360en2026-04-08T16:00:00.000ZUK formalizes zero tariffs deal with US, will pay more for drugshttps://www.pharmaradar360.com/article/42c4a359fb6c3c85PharmaRadar360en2026-04-08T12:00:00.000ZShujie Yang harnesses sound to build the next generation of microrobotic medicinehttps://www.pharmaradar360.com/article/1e8b5d1ef6c358f2PharmaRadar360en2026-04-08T12:00:00.000ZExdensur (depemokimab) approved in China for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP)https://www.pharmaradar360.com/article/d1140638ffe45faaPharmaRadar360en2026-04-08T12:00:00.000ZBOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Yearhttps://www.pharmaradar360.com/article/443bc79f436d33cfPharmaRadar360en2026-04-08T11:01:00.000ZPrecision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conferencehttps://www.pharmaradar360.com/article/9e1cab0f347c6ff0PharmaRadar360en2026-04-08T11:00:00.000ZPesticides may wreak havoc on the gut microbiomehttps://www.pharmaradar360.com/article/27f581eeb745bbb2PharmaRadar360en2026-04-08T10:12:51.000ZLOTUS PREMIUM HONEY MIXED HERBAL PASTE WITH HONEYhttps://www.pharmaradar360.com/article/88ec9cf4278c12f1PharmaRadar360en2026-04-08T10:12:08.000ZBoletín sobre Medicamentos Veterinarios. Enero-Marzo 2026https://www.pharmaradar360.com/article/b4238f6419360b65PharmaRadar360en2026-04-08T10:00:00.000ZErratum for the Research Article "Extracellular vesicle-mediated gene editing for the treatment of nonsyndromic progressive hearing loss in adult mice"https://www.pharmaradar360.com/article/9f20c73c9d67380cPharmaRadar360en2026-04-08T10:00:00.000ZDesign of a neutralizing and protective pan-encephalitic alphavirus receptor decoy proteinhttps://www.pharmaradar360.com/article/6c060b0d51cb0d7cPharmaRadar360en2026-04-08T10:00:00.000ZReal-time intraocular pressure monitoring and responsive drug release in preclinical models by an all-polymer smart contact lenshttps://www.pharmaradar360.com/article/23ad693433b42951PharmaRadar360en2026-04-08T10:00:00.000ZKeratin 16 inhibits type I interferon responses in differentiating keratinocytes of stressed and diseased skinhttps://www.pharmaradar360.com/article/f99fbff449a04461PharmaRadar360en2026-04-08T10:00:00.000ZA human iPSC model of tauopathies engineered for 4R tau isoform expression endogenously develops late-stage neuronal tau pathologyhttps://www.pharmaradar360.com/article/568e3f0bfb57acb7PharmaRadar360en2026-04-08T10:00:00.000ZPharmacological activation of WASp potentiates macrophage phagocytosis and enhances ibrutinib efficacy against mouse models of brain tumorshttps://www.pharmaradar360.com/article/e5f39655837889edPharmaRadar360en2026-04-08T10:00:00.000ZCorticosteroid resistance is predetermined by early immune response dynamics at acute graft-versus-host disease onsethttps://www.pharmaradar360.com/article/3ae566c61a3aceccPharmaRadar360en2026-04-08T10:00:00.000ZMore about the Phase 2a Study of Baxdrostat in Primary Aldosteronismhttps://www.pharmaradar360.com/article/e931da715517860ePharmaRadar360en2026-04-08T10:00:00.000ZCD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia. Replyhttps://www.pharmaradar360.com/article/f0edfb56568a5ae2PharmaRadar360en2026-04-08T10:00:00.000ZCD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemiahttps://www.pharmaradar360.com/article/1553c8bf38ae6911PharmaRadar360en2026-04-08T10:00:00.000ZHigh-Dose Influenza Vaccine and Hospitalizations in Older Adults. Replyhttps://www.pharmaradar360.com/article/771841d240dc211fPharmaRadar360en2026-04-08T10:00:00.000ZTrends in Youth-Onset Type 2 Diabetes, 2013-2024https://www.pharmaradar360.com/article/ddec4f1f2cbfda7cPharmaRadar360en2026-04-08T10:00:00.000ZAltering the Diet to Rewire Cancerhttps://www.pharmaradar360.com/article/8ba4c0327bf4cd39PharmaRadar360en2026-04-08T10:00:00.000ZCase 10-2026: A 70-Year-Old Woman with a Racing Heart, Fatigue, and Dyspneahttps://www.pharmaradar360.com/article/6ed29ad97a8466c1PharmaRadar360en2026-04-08T10:00:00.000ZNecrolytic Migratory Erythemahttps://www.pharmaradar360.com/article/3c43992be699dafdPharmaRadar360en2026-04-08T10:00:00.000ZCeliac Diseasehttps://www.pharmaradar360.com/article/3c8fa9f878fb648cPharmaRadar360en2026-04-08T10:00:00.000ZThe Ultimate Guide to New USP Bioburden Standards: Navigating Compliance & Market Success in 2026https://www.pharmaradar360.com/article/f892b53d062c370aPharmaRadar360en2026-04-08T10:00:00.000ZPhase 1/1b study of BCMA-targeting bispecific T-cell engager pavurutamab in relapsed/refractory multiple myelomahttps://www.pharmaradar360.com/article/b3478b977ddc5c35PharmaRadar360en2026-04-08T10:00:00.000ZTunneling Nanotube-Mediated Filamin A Transport Mechanosensitively Programs Osteoclastogenesis in Myeloma Bone Diseasehttps://www.pharmaradar360.com/article/06bfc455ca34cd02PharmaRadar360en2026-04-08T10:00:00.000ZA tumor suppressor role of the miR-15b/16-2 cluster in T-cell acute lymphoblastic leukemiahttps://www.pharmaradar360.com/article/076b4526c20d9008PharmaRadar360en2026-04-08T10:00:00.000ZSevere allergic transfusion reactions to B/AB plasma or platelets in group O recipients are linked to α‑Gal sensitizationhttps://www.pharmaradar360.com/article/ed155f96a7ec067aPharmaRadar360en2026-04-08T10:00:00.000ZNuclear Transcriptional Condensates as Drivers and Therapeutic Targets in NPM1-mutated AMLhttps://www.pharmaradar360.com/article/807fed661fe6be5bPharmaRadar360en2026-04-08T10:00:00.000ZMYB activity drives emergent enhancer activation and enhancer-promoter interactions in acute lymphoblastic leukemiahttps://www.pharmaradar360.com/article/0735d31535df2708PharmaRadar360en2026-04-08T09:37:32.000ZDigital upgrade to histopathology service reduces wait time for cancer diagnosishttps://www.pharmaradar360.com/article/2beb101652671abbPharmaRadar360en2026-04-08T09:24:44.000ZΑνάκληση της παρτίδας 111572333 βρεφικού γάλακτος ALMIRON PROFUTURA 1https://www.pharmaradar360.com/article/b529e0a735901334PharmaRadar360en2026-04-08T09:16:18.000ZFDA Seeks Input on Digital Health Technologies in Clinical Investigations for Drugs and Biological Productshttps://www.pharmaradar360.com/article/3cec82220bed3099PharmaRadar360en2026-04-08T09:06:54.000ZΑνάκληση παρτίδων του ιατροτεχνολογικού προϊόντος VELFIX EDGE 6cmX7cm (REF 5502A) Διάθεση στην αγορά: NEUROMED MEDICAL SUPPLIEShttps://www.pharmaradar360.com/article/833e6dcf57ac829bPharmaRadar360en2026-04-08T08:00:14.000ZΕΚΣΤΡΑΤΕΙΑ ΕΝΗΜΕΡΩΣΗΣ ΓΙΑ ΤΗΝ ΑΣΦΑΛΕΙΑ ΤΩΝ ΚΤΗΝΙΑΤΡΙΚΩΝ ΦΑΡΜΑΚΩΝhttps://www.pharmaradar360.com/article/5d845a3a6343893cPharmaRadar360en2026-04-08T07:00:10.000ZNotice Regarding Issuance of New Shares and Secondary Offering of Shareshttps://www.pharmaradar360.com/article/aec189315eaa11ecPharmaRadar360en2026-04-08T07:00:00.000ZNotice Regarding Refinancing of Existing Borrowings through a Bridge Loanhttps://www.pharmaradar360.com/article/3a5608b3cf4ad8b3PharmaRadar360en2026-04-08T02:00:00.000ZPharmac funds medicine to reduce complications following allogenic haematopoietic stem cell transplanthttps://www.pharmaradar360.com/article/9d0367961f54bf35PharmaRadar360en2026-04-08T02:00:00.000ZPharmac invites feedback before possible medicine brand changeshttps://www.pharmaradar360.com/article/1206876d41c64f06PharmaRadar360en2026-04-08T00:00:00.000ZStatement by Dr Hanan Balkhy, WHO Regional Director at the emergencies presserhttps://www.pharmaradar360.com/article/2accff71dcba45e3PharmaRadar360en2026-04-08T00:00:00.000ZUroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancerhttps://www.pharmaradar360.com/article/d5db02d054e6bdaaPharmaRadar360en2026-04-08T00:00:00.000ZUnited Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failurehttps://www.pharmaradar360.com/article/1a7d6957c0fca353PharmaRadar360en2026-04-08T00:00:00.000ZShionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threatshttps://www.pharmaradar360.com/article/78bb0fe214831903PharmaRadar360en2026-04-08T00:00:00.000ZESCMID Global 2026: Shionogi presents new real-world data highlighting clinical effectiveness of Fetroja®/Fetcroja® (cefiderocol) in MBL-producing Enterobacterales infectionshttps://www.pharmaradar360.com/article/78082b9ada794671PharmaRadar360en2026-04-08T00:00:00.000ZInternal linkProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Eventhttps://www.pharmaradar360.com/article/92100c2e940d1f7ePharmaRadar360en2026-04-08T00:00:00.000ZInternal linkProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Boardhttps://www.pharmaradar360.com/article/58c4293d7e6ae0e0PharmaRadar360en2026-04-08T00:00:00.000ZInternal linkDownload presentationhttps://www.pharmaradar360.com/article/3f3eeedf2e4dbc0fPharmaRadar360en2026-04-08T00:00:00.000ZIdentification of biomarkers for non-invasive diagnosis and risk stratification in prostate cancer using NMR-based metabolomics and machine learninghttps://www.pharmaradar360.com/article/606d87faf7973cd3PharmaRadar360en2026-04-08T00:00:00.000ZHigh-throughput screening identifies NT-1 that synergizes with MRTX1133 against acquired resistant KRAS G12D colorectal cancerhttps://www.pharmaradar360.com/article/61e44e2d3a479f87PharmaRadar360en2026-04-08T00:00:00.000ZPharma Research & Developmenthttps://www.pharmaradar360.com/article/8a0650016ecd788cPharmaRadar360en2026-04-08T00:00:00.000ZIR and Shareholder Contactshttps://www.pharmaradar360.com/article/2ab32e39f49e794ePharmaRadar360en2026-04-08T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/7cdc1587cc697343PharmaRadar360en2026-04-08T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/d87163092f5776d6PharmaRadar360en2026-04-08T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/9b02a94f018cf4f0PharmaRadar360en2026-04-08T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/bc6c3b894a4fddcbPharmaRadar360en2026-04-08T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/07144feb113d0adfPharmaRadar360en2026-04-08T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/1b2284bdc218fbd8PharmaRadar360en2026-04-08T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/c8ad17fcf3af9e45PharmaRadar360en2026-04-08T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/dca87101a6b8ae58PharmaRadar360en2026-04-08T00:00:00.000ZHow we inventhttps://www.pharmaradar360.com/article/5770dc1080103a94PharmaRadar360en2026-04-08T00:00:00.000ZTranslational medicinehttps://www.pharmaradar360.com/article/6f6148bc4ab3c203PharmaRadar360en2026-04-08T00:00:00.000ZISPOR 2026 Plenaries and Speakers Announcedhttps://www.pharmaradar360.com/article/2e9a38805f5ff0d8PharmaRadar360en2026-04-08T00:00:00.000ZSome Common IBS Treatments Linked to Higher Risk of DeathApril08,2026 02:00 AMAmerica/Los_AngelesA large, long-term study led byCedars-Sinai Health Sciences…Read morehttps://www.pharmaradar360.com/article/506837b15a18950dPharmaRadar360en2026-04-08T00:00:00.000ZPress Release April 8, 2026Baxter to Host First-Quarter 2026 Financial Results Conference Call for Investorshttps://www.pharmaradar360.com/article/3e8184c0c0b6e329PharmaRadar360en2026-04-07T20:01:00.000ZAmneal to Report First Quarter 2026 Results on May 1, 2026https://www.pharmaradar360.com/article/9408431688daa48fPharmaRadar360en2026-04-07T17:51:28.934ZEasy Ways to Spot Spring Allergieshttps://www.pharmaradar360.com/article/61b13122a190cac7PharmaRadar360en2026-04-07T16:00:00.000ZKennedy sidestepping court order sidelining ACIP?https://www.pharmaradar360.com/article/46d318d12d5b11cdPharmaRadar360en2026-04-07T15:46:23.000ZDecision: Human and veterinary medicines: register of licensed manufacturing siteshttps://www.pharmaradar360.com/article/3d3d773b50e88351PharmaRadar360en2026-04-07T15:45:00.000ZTransgene to Participate in Upcoming Investor Meetingshttps://www.pharmaradar360.com/article/36904b3f97761ee5PharmaRadar360en2026-04-07T15:25:08.000ZDecision: Medicines: new manufacturing and wholesale dealer licenceshttps://www.pharmaradar360.com/article/795c36db0193809dPharmaRadar360en2026-04-07T15:25:00.000ZNotice: Medicines: terminated and cancelled manufacturing and wholesale dealer licenceshttps://www.pharmaradar360.com/article/faed43e9e1789450PharmaRadar360en2026-04-07T15:24:49.000ZDecision: Human medicines: register of licensed wholesale distribution siteshttps://www.pharmaradar360.com/article/21a6edec1caf7afaPharmaRadar360en2026-04-07T15:11:58.000ZFind product information about medicineshttps://www.pharmaradar360.com/article/e1a37f7084840d78PharmaRadar360en2026-04-07T15:00:00.000ZSector tariff now more than a threat – for some Rx companieshttps://www.pharmaradar360.com/article/69a247d6c040ae71PharmaRadar360en2026-04-07T13:00:00.000ZMerck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.https://www.pharmaradar360.com/article/498d71c381684fc9PharmaRadar360en2026-04-07T13:00:00.000ZAllergan Aesthetics Third State-of-the-Art AMI Center Opens in Austinhttps://www.pharmaradar360.com/article/5c3ff9f103b0677bPharmaRadar360en2026-04-07T12:30:00.000ZAbeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directorshttps://www.pharmaradar360.com/article/b73fdd388f8735ddPharmaRadar360en2026-04-07T12:05:00.000ZEmergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparednesshttps://www.pharmaradar360.com/article/db856c0240490cc2PharmaRadar360en2026-04-07T12:00:00.000ZNatac’s CEO presents SustaiNext as an example of industrial scale-up at the CBE JU Stakeholder Forum 202607/04/2026Industrial biotechnologyAntonio Delgado participated in the panel “From lab to fab: enabling scale up of bio-based…Partners - Natac Grouphttps://www.pharmaradar360.com/article/22c8686631dc1d90PharmaRadar360en2026-04-07T12:00:00.000ZAmneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Monthhttps://www.pharmaradar360.com/article/2793b7abb7a8a835PharmaRadar360en2026-04-07T11:31:09.000ZΑΝΑΚΟΙΝΩΣΗ – ΔΙΑΚΟΠΗ ΗΛΕΚΤΡΟΝΙΚΩΝ ΥΠΗΡΕΣΙΩΝhttps://www.pharmaradar360.com/article/cdd7493356f30112PharmaRadar360en2026-04-07T11:11:33.000ZLa AEMPS recuerda las condiciones para obtener la licencia previa de funcionamiento para la fabricación a terceros de productos sanitarios y productos sanitarios para diagnóstico in vitro